Skip to main content
Sister Publication Links
  • ModernHealthcare.com
Subscribe
  • My Account
  • Login
  • Register
  • Consumer Centric
  • Provider/Payer Centric
  • Funding/M&A
  • Policy
  • Data
  • Opinion
  • MORE+
    • Webinars
    • Advertise
MENU
Breadcrumb
  1. Home
  2. Finance
January 04, 2023 06:00 AM

A tough year for insurtechs raises questions about the future

Nona Tepper
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Insuretech_NT.png
    MH Illustration/iStock

    Startup health insurers spent 2022 scaling back their businesses as investors are no longer willing to contribute the billions of dollars necessary for subsidizing them. Insurtechs Oscar Health, Clover Health and Bright Health Group’s failure to thrive at a time when most health insurers are making more money than ever has left some wondering what their future holds.

    While Oscar Health, Clover Health and Bright Health all have different core businesses, their origins are largely the same. Founders who generally lacked healthcare experience started health insurance companies around the time the Affordable Care Act's exchanges went live in 2014, promising to disrupt coverage available in the new marketplaces and to capitalize on the growing Medicare Advantage program.

    The companies pitched using technology to modernize a big, unloved industry dominated by legacy players. Of the $4.3 trillion in the U.S. spent on healthcare in 2021, approximately two-thirds flowed through health insurers, according to the most recent federal data. “Now is a unique moment to create a company that is relentlessly focused on serving members. We had to disrupt one of the largest industries in our country,” Oscar Health co-founder Josh Kushner said during its investor roadshow in February 2021.

    Read the complete story at Modern Healthcare

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it online.

    Recommended for You
    Alyssa Jaffee
    Five Questions: 7wireVentures’ Alyssa Jaffee
    money2_i_i.png
    GeneDx to raise $150M in public and direct stock offerings
    Sponsored Content
    Get Newsletters

    Newsletters for providers, payers, investors and innovators across the digital health ecosystem. Sign up to get breaking digital health news including digital health deals, M&A, finance, IPOs. as they happen, right to your inbox.

    Buy Q3 Report Today
    Quarterly Report Cover Image

    The Digital Health Funding and M&A Q3 report delivers the most comprehensive insight and data around the financial health of the sector.

    Purchase Today
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Digital Health Business & Technology delivers news, data, insights and analysis covering the entire digital healthcare ecosystem.

    Logo
    Contact Us

    (877) 812-1581

    Email us

     

    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    Resources
    • About Us
    • Contact Us
    • Staff
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Digital Health Business & Technology
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • Consumer Centric
    • Provider/Payer Centric
    • Funding/M&A
    • Policy
    • Data
    • Opinion
    • MORE+
      • Webinars
      • Advertise